Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
Executive Summary
The primary efficacy endpoint in comparative antihypertensive trials should shift from diastolic blood pressure measured at trough levels to systolic blood pressure at trough, FDA's Cardiovascular & Renal Drugs Advisory Committee member Steven Nissen, MD, suggested July 18